By Fineline Cube Shanghai Henlius Biotech Inc. (HKG: 2696) announced it has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase I clinical study evaluating its HLX05-N biosimilar—a copy of Merck KGaA’s Erbitux (cetuximab)—in patients with metastatic colorectal cancer (mCRC).
Regulatory & Development Timeline
| Milestone | Jurisdiction | Status |
|---|---|---|
| Chinese Clinical Trial Approval | NMPA (China) | Granted April 2026 |
| U.S. IND Clearance | FDA (United States) | Granted May 2026 |
| Reference Product | Erbitux (cetuximab) | Merck KGaA/Daiichi Sankyo |
| Target Indication | Metastatic Colorectal Cancer (mCRC) | First-line and refractory settings |
This dual-jurisdiction approval strategy positions Henlius to pursue simultaneous development pathways in both the world’s largest pharmaceutical markets.
Drug Mechanism & Therapeutic Profile
Molecular Target & Action
- Target: Epidermal Growth Factor Receptor (EGFR) expressed on normal and tumor cells
- Mechanism: Competitive inhibition of ligand binding (EGF, TGF-α) to EGFR
- Downstream Effects:
- Blocks receptor phosphorylation and kinase activation
- Inhibits tumor cell proliferation and growth
- Induces programmed cell death (apoptosis)
- Reduces matrix metalloproteinase production
- Decreases vascular endothelial growth factor (VEGF) expression
Clinical Significance in mCRC
Cetuximab represents a cornerstone therapy in EGFR-positive metastatic colorectal cancer, particularly in RAS wild-type patients. The biosimilar HLX05-N aims to provide cost-effective access to this established biologic while maintaining comparable efficacy and safety profiles.
Strategic Market Implications
- Biosimilar Opportunity: U.S. cetuximab market valued at approximately $1.2 billion annually, with patent expiration creating significant biosimilar entry opportunities
- Global Development Strategy: FDA clearance validates Henlius’ international regulatory capabilities and quality standards
- Competitive Landscape: Positions Henlius among leading Chinese biosimilar developers targeting Western markets, alongside companies like Innovent and Bio-Thera Solutions
- Revenue Diversification: Successful U.S. approval could contribute $200-400 million in annual revenue by 2030, representing 15-25% of current company revenue
The Phase I trial will primarily assess safety, pharmacokinetics, and immunogenicity compared to the reference Erbitux product, with subsequent phases planned to demonstrate clinical equivalence in larger patient populations.
Forward-Looking Statements
This brief contains forward-looking statements regarding clinical development timelines, regulatory approvals, and commercial potential for HLX05-N. Actual results may differ due to clinical trial outcomes, regulatory decisions, and competitive dynamics in the oncology biosimilar market.-Fineline Info & Tech